Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Share-based Compensation (2016 - 2025)

Traws Pharma (TRAW) has disclosed Share-based Compensation for 14 consecutive years, with $327000.0 as the latest value for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 2.1% year-over-year to $327000.0; the TTM value through Dec 2025 reached $728000.0, down 47.63%, while the annual FY2025 figure was $728000.0, 47.63% down from the prior year.
  • Share-based Compensation hit $327000.0 in Q4 2025 for Traws Pharma, up from $135000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $380000.0 in Q2 2024 and bottomed at $60000.0 in Q2 2021.
  • Average Share-based Compensation over 5 years is $257150.0, with a median of $292500.0 recorded in 2022.
  • Year-over-year, Share-based Compensation skyrocketed 355.38% in 2022 and then plummeted 72.37% in 2025.
  • Traws Pharma's Share-based Compensation stood at $261000.0 in 2021, then rose by 26.44% to $330000.0 in 2022, then grew by 0.61% to $332000.0 in 2023, then grew by 0.6% to $334000.0 in 2024, then decreased by 2.1% to $327000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $327000.0, $135000.0, and $105000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.